There’s something quietly lethal about a startup that shows up in a legacy industry with tech that doesn’t just improve outcomes, it dares to challenge the entire method of treatment. Liquet Medical isn’t here to impress the crowd with noise. They’re too busy building a future where blood clots in the lungs get the kind of real-time, precision-guided therapy that feels more NASA than 1990s medical protocol.
Co-founders John Schindler and Derek Hall didn’t come into this with a pitch deck and a dream. They came with decades of trench work, John with 30+ years of hard-won experience across Atrium Medical, Maquet Medical Systems, and the Getinge Group. Derek brings the engineering firepower and the regulatory know-how that turns ideas into devices and devices into cleared technologies. This isn’t their first device rodeo, but it might just be their most important.
Their Versus™ Catheter isn’t just another tube in a crowded medtech drawer. It’s a dual-tipped, real-time pressure monitoring, hemodynamics-led, bilateral beast of a system, designed to treat both lungs at once with the kind of data feedback that’s long been missing in pulmonary embolism care. FDA said yes in December 2024. The pilot study kicks off this summer at University of Virginia Hospital. The rest of the industry? Still trying to catch its breath.
The real story here isn’t just the device, it’s the momentum. An oversubscribed Seed round closed in May 2025. Virginia Innovation Partnership Corporation, via its Virginia Venture Partners program, led the charge. Alex Euler didn’t just bet on Liquet Medical, he’s now a board observer keeping a front-row seat to the playbook. You don’t do that unless you believe what you’re seeing is big.
Look deeper and you’ll find more than capital and clearances. You’ll find a board stacked with operators who’ve taken companies from the garage to exit, including Dr. Gabriele Niederauer, Bill Porter, and Dr. Paul Sartori. You’ll find regulatory heavyweights like Dr. Carrie Kuehn guiding 510(k) strategy like a maestro. You’ll find clinical vision backed by the very doctor who invented the catheter, Dr. Patrick Kelly.
Liquet Medical’s not chasing market size, they’re addressing the nearly 900,000 Americans impacted by pulmonary embolism each year with tools built for actual, responsive care. It’s a $3.5M+ war chest aimed at turning one of the deadliest cardiovascular killers into something treatable, trackable, and personalized. Because static protocols don’t cut it anymore. Real-time matters. Precision matters. Lives are on the line.
Pulmonary embolism might be a mouthful. Liquet makes treating it look surgical.
